Build Your Comparison

Side-by-side financial analysis
EQ logo
EQ
ABBV logo
ABBV
KO logo
KO
JPM logo
JPM
Try popular comparisons:

Stock Comparison

EQ vs ABBV vs KO vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
EQ
Equillium, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$271M
5Y Perf.-4.7%
ABBV
AbbVie Inc.

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$397.56B
5Y Perf.+132.0%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.22B
5Y Perf.+84.9%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$875.80B
5Y Perf.+241.0%

EQ vs ABBV vs KO vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
EQ logoEQ
ABBV logoABBV
KO logoKO
JPM logoJPM
IndustryBiotechnologyDrug Manufacturers - GeneralBeverages - Non-AlcoholicBanks - Diversified
Market Cap$271M$397.56B$355.22B$875.80B
Revenue (TTM)$0.00$61.16B$49.28B$280.33B
Net Income (TTM)$-19M$4.23B$13.70B$57.05B
Gross Margin70.2%61.7%60.0%
Operating Margin26.7%29.3%25.9%
Forward P/E16.0x25.2x14.1x
Total Debt$719K$69.07B$45.49B$942.38B
Cash & Equiv.$30M$5.23B$10.27B$343.34B

EQ vs ABBV vs KO vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

EQ
ABBV
KO
JPM
StockJun 20Jun 26Return
Equillium, Inc. (EQ)10095.3-4.7%
AbbVie Inc. (ABBV)100232.0+132.0%
The Coca-Cola Compa… (KO)100184.9+84.9%
JPMorgan Chase & Co. (JPM)100341.0+241.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: EQ vs ABBV vs KO vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ABBV leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. The Coca-Cola Company is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. EQ and JPM also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇ABBV emerged as the overall leader. Track its performance:
EQ
Equillium, Inc.
The Defensive Pick

EQ is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 0.50, Low D/E 2.5%, current ratio 10.32x
  • +6.3% vs KO's +17.4%
Best for: sleep-well-at-night
ABBV
AbbVie Inc.
The Income Pick

ABBV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 43 yrs, beta 0.15, yield 2.9%
  • Rev growth 8.6%, EPS growth -0.8%, 3Y rev CAGR 1.8%
  • Beta 0.15, yield 2.9%, current ratio 0.67x
  • 8.6% revenue growth vs EQ's -100.0%
Best for: income & stability and growth exposure
KO
The Coca-Cola Company
The Quality Compounder

KO is the #2 pick in this set and the best alternative if quality and efficiency is your priority.

  • 27.8% margin vs EQ's 2.6%
  • 13.1% ROA vs EQ's -53.7%, ROIC 15.8% vs -88.8%
Best for: quality and efficiency
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is long-term compounding and valuation efficiency.

  • 454.4% 10Y total return vs ABBV's 357.3%
  • PEG 1.08 vs KO's 2.26
  • Lower P/E (14.1x vs 25.2x), PEG 1.08 vs 2.26
Best for: long-term compounding and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthABBV logoABBV8.6% revenue growth vs EQ's -100.0%
ValueJPM logoJPMLower P/E (14.1x vs 25.2x), PEG 1.08 vs 2.26
Quality / MarginsKO logoKO27.8% margin vs EQ's 2.6%
Stability / SafetyABBV logoABBVBeta 0.15 vs JPM's 0.95
DividendsABBV logoABBV2.9% yield, 43-year raise streak, vs KO's 2.5%, (1 stock pays no dividend)
Momentum (1Y)EQ logoEQ+6.3% vs KO's +17.4%
Efficiency (ROA)KO logoKO13.1% ROA vs EQ's -53.7%, ROIC 15.8% vs -88.8%

EQ vs ABBV vs KO vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
EQEquillium, Inc.

Segment breakdown not available.

ABBVAbbVie Inc.
FY 2025
SKYRIZI
30.2%$17.6B
RINVOQ
14.3%$8.3B
H U M I R A
7.8%$4.5B
Botox Therapeutic
6.5%$3.8B
Vraylar
6.2%$3.6B
Imbruvica
4.9%$2.9B
VENCLEXTA
4.8%$2.8B
Other (14)
25.3%$14.7B
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

EQ vs ABBV vs KO vs JPM — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGABBV

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 3 of 6 comparable metrics.

JPM and EQ operate at a comparable scale, with $280.3B and $0 in trailing revenue. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to ABBV's 6.9%.

MetricEQ logoEQEquillium, Inc.ABBV logoABBVAbbVie Inc.KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$0$61.2B$49.3B$280.3B
EBITDAEarnings before interest/tax-$20M$24.5B$15.5B$81.4B
Net IncomeAfter-tax profit-$19M$4.2B$13.7B$57.0B
Free Cash FlowCash after capex-$19M$18.7B$12.6B$100.9B
Gross MarginGross profit ÷ Revenue+70.2%+61.7%+60.0%
Operating MarginEBIT ÷ Revenue+26.7%+29.3%+25.9%
Net MarginNet income ÷ Revenue+6.9%+27.8%+20.4%
FCF MarginFCF ÷ Revenue+30.6%+25.5%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+10.0%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+77.0%+57.4%+18.2%+16.0%
KO leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

JPM leads this category, winning 5 of 7 comparable metrics.

At 15.6x trailing earnings, JPM trades at a 84% valuation discount to ABBV's 94.8x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 1.20x vs KO's 2.43x — a lower PEG means you pay less per unit of expected earnings growth.

MetricEQ logoEQEquillium, Inc.ABBV logoABBVAbbVie Inc.KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
Market CapShares × price$271M$397.6B$355.2B$875.8B
Enterprise ValueMkt cap + debt − cash$241M$461.4B$390.4B$1.47T
Trailing P/EPrice ÷ TTM EPS-7.21x94.84x27.15x15.64x
Forward P/EPrice ÷ next-FY EPS est.15.96x25.24x14.08x
PEG RatioP/E ÷ EPS growth rate2.43x1.20x
EV / EBITDAEnterprise value multiple16.34x26.36x18.11x
Price / SalesMarket cap ÷ Revenue6.50x7.41x3.13x
Price / BookPrice ÷ Book value/share9.03x10.39x2.42x
Price / FCFMarket cap ÷ FCF22.32x67.07x8.68x
JPM leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

Evenly matched — EQ and ABBV and KO each lead in 3 of 9 comparable metrics.

ABBV delivers a 62.1% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $-61 for EQ. EQ carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs EQ's 1/9, reflecting strong financial health.

MetricEQ logoEQEquillium, Inc.ABBV logoABBVAbbVie Inc.KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-61.4%+62.1%+41.1%+15.9%
ROA (TTM)Return on assets-53.7%+3.1%+13.1%+1.3%
ROICReturn on invested capital-88.8%+23.9%+15.8%+4.5%
ROCEReturn on capital employed-98.1%+21.5%+17.3%+8.9%
Piotroski ScoreFundamental quality 0–91675
Debt / EquityFinancial leverage0.03x1.33x2.60x
Net DebtTotal debt minus cash-$30M$63.8B$35.2B$599.0B
Cash & Equiv.Liquid assets$30M$5.2B$10.3B$343.3B
Total DebtShort + long-term debt$719,000$69.1B$45.5B$942.4B
Interest CoverageEBIT ÷ Interest expense3.28x10.70x0.74x
Evenly matched — EQ and ABBV and KO each lead in 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

EQ leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ABBV five years ago would be worth $22,106 today (with dividends reinvested), compared to $4,584 for EQ. Over the past 12 months, EQ leads with a +628.0% total return vs KO's +17.4%. The 3-year compound annual growth rate (CAGR) favors EQ at 58.2% vs KO's 13.7% — a key indicator of consistent wealth creation.

MetricEQ logoEQEquillium, Inc.ABBV logoABBVAbbVie Inc.KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date+83.7%-0.5%+20.2%-2.8%
1-Year ReturnPast 12 months+628.0%+20.9%+17.4%+19.1%
3-Year ReturnCumulative with dividends+295.8%+77.1%+46.9%+133.1%
5-Year ReturnCumulative with dividends-54.2%+121.1%+63.6%+110.0%
10-Year ReturnCumulative with dividends-79.9%+357.3%+120.9%+454.4%
CAGR (3Y)Annualised 3-year return+58.2%+21.0%+13.7%+32.6%
EQ leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.15 beta — it tends to amplify market swings less than JPM's 0.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.2% from its 52-week high vs EQ's 81.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricEQ logoEQEquillium, Inc.ABBV logoABBVAbbVie Inc.KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5000.58x0.14x-0.20x0.94x
52-Week HighHighest price in past year$3.43$244.81$84.04$337.25
52-Week LowLowest price in past year$0.27$181.73$65.35$262.71
% of 52W HighCurrent price vs 52-week peak+81.9%+91.8%+98.2%+93.0%
RSI (14)Momentum oscillator 0–10053.563.265.754.8
Avg Volume (50D)Average daily shares traded559K4.6M12.6M7.0M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — ABBV and KO each lead in 1 of 2 comparable metrics.

Analyst consensus: EQ as "Buy", ABBV as "Buy", KO as "Buy", JPM as "Buy". Consensus price targets imply 122.4% upside for EQ (target: $6) vs 4.6% for KO (target: $86). For income investors, ABBV offers the higher dividend yield at 2.92% vs JPM's 1.90%.

MetricEQ logoEQEquillium, Inc.ABBV logoABBVAbbVie Inc.KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$6.25$256.92$86.29$338.78
# AnalystsCovering analysts12414861
Dividend YieldAnnual dividend ÷ price+2.9%+2.5%+1.9%
Dividend StreakConsecutive years of raises435615
Dividend / ShareAnnual DPS$6.57$2.04$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.2%+0.2%+3.9%
Evenly matched — ABBV and KO each lead in 1 of 2 comparable metrics.
Key Takeaway

KO leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). JPM leads in 1 (Valuation Metrics). 2 tied.

Best OverallThe Coca-Cola Company (KO)Leads 2 of 6 categories
Loading custom metrics...

EQ vs ABBV vs KO vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is EQ or ABBV or KO or JPM a better buy right now?

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -100. 0% for Equillium, Inc. (EQ). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Equillium, Inc. (EQ) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — EQ or ABBV or KO or JPM?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 6x versus AbbVie Inc. at 94. 8x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 1. 08x versus The Coca-Cola Company's 2. 26x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — EQ or ABBV or KO or JPM?

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +121. 1%, compared to -54. 2% for Equillium, Inc. (EQ). Over 10 years, the gap is even starker: JPM returned +465. 8% versus EQ's -79. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — EQ or ABBV or KO or JPM?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately -571% more volatile than KO relative to the S&P 500. On balance sheet safety, Equillium, Inc. (EQ) carries a lower debt/equity ratio of 3% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — EQ or ABBV or KO or JPM?

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus -100. 0% for Equillium, Inc. (EQ). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -69. 6% for Equillium, Inc.. Over a 3-year CAGR, KO leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — EQ or ABBV or KO or JPM?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus 0. 0% for Equillium, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus 0. 0% for EQ. At the gross margin level — before operating expenses — ABBV leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is EQ or ABBV or KO or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 1. 08x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 1x forward P/E versus 25. 2x for The Coca-Cola Company — 11. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EQ: 122. 4% to $6. 25.

08

Which pays a better dividend — EQ or ABBV or KO or JPM?

In this comparison, ABBV (2.

9% yield), KO (2. 5% yield), JPM (1. 9% yield) pay a dividend. EQ does not pay a meaningful dividend and should not be held primarily for income.

09

Is EQ or ABBV or KO or JPM better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, EQ: -79. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between EQ and ABBV and KO and JPM?

These companies operate in different sectors (EQ (Healthcare) and ABBV (Healthcare) and KO (Consumer Defensive) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EQ is a small-cap quality compounder stock; ABBV is a large-cap quality compounder stock; KO is a large-cap quality compounder stock; JPM is a large-cap deep-value stock. ABBV, KO, JPM pay a dividend while EQ does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.